Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion CN Bio, a
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform
CN Bio and Pharmaron partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel
FDA’s plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant methods
Implementation of this new regimen will begin immediately for investigational new drug (IND) applications, where the inclusion of NAMs data is now
CN Bio launches PhysioMimix® DILI assay kit: Human 24
CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced
CN Bio signs strategic partnership with Primetech Corporation to establish distribution channel for OOC solutions in Japan
Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise. Partnership solidifies CN Bio’s
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18
Unique solution enabling researchers to profile human oral drug bioavailability in vitro, in their own laboratories Cambridge, UK, 14 November
CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
Key appointment to support continued UK and US team expansion CN Bio, a leading provider of single- and multi-organ microphysiological systems,
CN Bio raises $21 million USD in first close of Series B investment round
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively. Investment will expand product
CN Bio selected for NC3R’s SensOoChip Challenge to develop advanced Heart-on-a-Chip
Part of the wider CRACK IT scheme – the multi-challenge competition aims to leverage CN Bio's existing OOC expertise - our MPS development and